CIK 0001231457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- 4 Grant or award Director acquired 3,460 shares (grant or award)
- 4 Grant or award Director acquired 3,460 shares (grant or award)
- 4 Grant or award Director acquired 6,920 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale 10% owner sold 52,616 shares at an average $22.23 ($1,169,868)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Head of Regulatory acquired 10,000 shares (grant or award)
- 4 Grant or award Head of Quality acquired 20,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Open-market sale 10% owner sold 37,277 shares at an average $23.57 ($878,600)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale VP, Clinical Trial Operations sold 19,800 shares at $24.70 ($489,060)
- 4 Open-market sale Head of Quality sold 515 shares at $23.73 ($12,221)
- 4 Open-market sale Head of Regulatory sold 935 shares at $23.73 ($22,188)
- 4 Open-market sale Chief Financial Officer sold 1,297 shares at $23.73 ($30,778)
- 4 Open-market sale General Counsel sold 328 shares at $23.73 ($7,783)
- 4 Open-market sale VP, Pharmaceutical Development sold 3,265 shares at $23.73 ($77,478)
Page 8 of 10 · 190 filings